Unopened GLP-1 pens stored correctly in the refrigerator at 2C to 8C remain stable until their printed expiry date
In a cohort of 3731 patients, weight loss of 5%, 10%, and 15% was observed in 63%, 33%, and 14%, respectively, after 56 weeks of treatment (27%, 11%, and 4% with placebo),69 or of an additional 6% at 56 weeks in patients who had already lost 6% through hypocaloric diet and exercise.70 Positive results were also observed in adolescent patients with obesity,71 and in real-life studies substantial weight loss has also been reported.7275 Phase 3 trials with GLP-1 receptor agonists indicated specifically for obesity and overweight
We verify benefits prior to your visit, ensuring transparency in cost expectations
On Tuesday morning, Eli Lilly reported that orforglipron met the benchmarks of the companys Phase III ATTAIN-2 study
Photos accompanying this announcement are available at:
Low and Slow Titration We start at the lowest dose, increase only when clinically appropriate, and work with you to find the lowest effective dose that delivers real results
